Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

Plasma microRNA Levels Combined with CEA and CA19-9 in the Follow-Up of Colorectal Cancer Patients

M. Pesta, R. Kucera, O. Topolcan, M. Karlikova, K. Houfkova, J. Polivka, T. Macanova, I. Machova, D. Slouka, V. Kulda,

. 2019 ; 11 (6) : . [pub] 20190621

Jazyk angličtina Země Švýcarsko

Typ dokumentu časopisecké články

Perzistentní odkaz   https://www.medvik.cz/link/bmc19028850

Grantová podpora
Conceptual Development of Research Organization (Faculty Hospital in Pilsen - FNPl, 00669806) Ministry of Health of the Czech Republic
Project - UNCE/MED/006 - Project Centrum of clinical and experimental liver surgery Charles University Fund

Colorectal cancer (CRC) ranks among the most common cancers worldwide. Surgical removal remains the best strategy for treatment of resectable tumors. An important part of caring for patients after surgery is monitoring for early detection of a possible relapse of the disease. Efforts are being made to improve the sensitivity and specificity of routinely used carcinoembryonic antigen (CEA) with the use of additional biomarkers such as microRNAs. The aim of our study was to evaluate the prognostic potential of microRNAs and their use as markers of disease recurrence. The quantitative estimation of CEA, CA19-9, and 22 selected microRNAs (TaqMan Advanced miRNA Assays) was performed in 85 paired (preoperative and postoperative) blood plasma samples of CRC patients and in samples taken during the follow-up period. We have revealed a statistically significant decrease in plasma levels for miR-20a, miR-23a, miR-210, and miR-223a (p = 0.0093, p = 0.0013, p = 0.0392, and p = 0.0214, respectively) after surgical removal of the tumor tissue. A statistically significant relation to prognosis (overall survival; OS) was recorded for preoperative plasma levels of miR-20a, miR-21, and miR-23a (p = 0.0236, p = 0.0316, and p =0.0271, respectively) in a subgroup of patients who underwent palliative surgery. The best discrimination between patients with favorable and unfavorable outcomes was achieved by a combination of CEA, CA19-9 with miR-21, miR-20a, and miR-23a (p < 0.0001). The use of these microRNAs for early disease recurrence detection was affected by a low specificity in comparison with CEA and CA19-9. CEA and CA19-9 had high specificity but low sensitivity. Our results show the benefit of combining currently used standard biomarkers and microRNAs for precise prognosis estimation.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc19028850
003      
CZ-PrNML
005      
20190815114650.0
007      
ta
008      
190813s2019 sz f 000 0|eng||
009      
AR
024    7_
$a 10.3390/cancers11060864 $2 doi
035    __
$a (PubMed)31234350
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a sz
100    1_
$a Pesta, Martin $u Department of Biology, Faculty of Medicine in Pilsen, Charles University, alej Svobody 76, 32300 Pilsen, Czech Republic. martin.pesta@lfp.cuni.cz. Laboratory of Immunoanalysis, University Hospital in Pilsen, E. Benese 13, 30599 Pilsen, Czech Republic. martin.pesta@lfp.cuni.cz.
245    10
$a Plasma microRNA Levels Combined with CEA and CA19-9 in the Follow-Up of Colorectal Cancer Patients / $c M. Pesta, R. Kucera, O. Topolcan, M. Karlikova, K. Houfkova, J. Polivka, T. Macanova, I. Machova, D. Slouka, V. Kulda,
520    9_
$a Colorectal cancer (CRC) ranks among the most common cancers worldwide. Surgical removal remains the best strategy for treatment of resectable tumors. An important part of caring for patients after surgery is monitoring for early detection of a possible relapse of the disease. Efforts are being made to improve the sensitivity and specificity of routinely used carcinoembryonic antigen (CEA) with the use of additional biomarkers such as microRNAs. The aim of our study was to evaluate the prognostic potential of microRNAs and their use as markers of disease recurrence. The quantitative estimation of CEA, CA19-9, and 22 selected microRNAs (TaqMan Advanced miRNA Assays) was performed in 85 paired (preoperative and postoperative) blood plasma samples of CRC patients and in samples taken during the follow-up period. We have revealed a statistically significant decrease in plasma levels for miR-20a, miR-23a, miR-210, and miR-223a (p = 0.0093, p = 0.0013, p = 0.0392, and p = 0.0214, respectively) after surgical removal of the tumor tissue. A statistically significant relation to prognosis (overall survival; OS) was recorded for preoperative plasma levels of miR-20a, miR-21, and miR-23a (p = 0.0236, p = 0.0316, and p =0.0271, respectively) in a subgroup of patients who underwent palliative surgery. The best discrimination between patients with favorable and unfavorable outcomes was achieved by a combination of CEA, CA19-9 with miR-21, miR-20a, and miR-23a (p < 0.0001). The use of these microRNAs for early disease recurrence detection was affected by a low specificity in comparison with CEA and CA19-9. CEA and CA19-9 had high specificity but low sensitivity. Our results show the benefit of combining currently used standard biomarkers and microRNAs for precise prognosis estimation.
655    _2
$a časopisecké články $7 D016428
700    1_
$a Kucera, Radek $u Laboratory of Immunoanalysis, University Hospital in Pilsen, E. Benese 13, 30599 Pilsen, Czech Republic. kucerar@fnplzen.cz. Department of Medical Chemistry and Biochemistry, Faculty of Medicine in Pilsen, Charles University, Karlovarska 48, 30166 Pilsen, Czech Republic. kucerar@fnplzen.cz.
700    1_
$a Topolcan, Ondrej $u Laboratory of Immunoanalysis, University Hospital in Pilsen, E. Benese 13, 30599 Pilsen, Czech Republic. topolcan@fnplzen.cz.
700    1_
$a Karlikova, Marie $u Laboratory of Immunoanalysis, University Hospital in Pilsen, E. Benese 13, 30599 Pilsen, Czech Republic. karlikovam@fnplzen.cz.
700    1_
$a Houfkova, Katerina $u Department of Biology, Faculty of Medicine in Pilsen, Charles University, alej Svobody 76, 32300 Pilsen, Czech Republic. katerina.houfkova@lfp.cuni.cz.
700    1_
$a Polivka, Jiri $u Laboratory of Immunoanalysis, University Hospital in Pilsen, E. Benese 13, 30599 Pilsen, Czech Republic. jiri.polivka@lfp.cuni.cz. Department of Histology and Embryology, Faculty of Medicine in Pilsen, Charles University, Karlovarska 48, 30166 Pilsen, Czech Republic. jiri.polivka@lfp.cuni.cz.
700    1_
$a Macanova, Tereza $u Department of Biology, Faculty of Medicine in Pilsen, Charles University, alej Svobody 76, 32300 Pilsen, Czech Republic. tereza.macanova@lfp.cuni.cz.
700    1_
$a Machova, Iva $u Laboratory of Immunoanalysis, University Hospital in Pilsen, E. Benese 13, 30599 Pilsen, Czech Republic. iva.machova@lfp.cuni.cz.
700    1_
$a Slouka, David $u Laboratory of Immunoanalysis, University Hospital in Pilsen, E. Benese 13, 30599 Pilsen, Czech Republic. slouka@fnplzen.cz.
700    1_
$a Kulda, Vlastimil $u Department of Medical Chemistry and Biochemistry, Faculty of Medicine in Pilsen, Charles University, Karlovarska 48, 30166 Pilsen, Czech Republic. vlastimil.kulda@lfp.cuni.cz.
773    0_
$w MED00173178 $t Cancers $x 2072-6694 $g Roč. 11, č. 6 (2019)
856    41
$u https://pubmed.ncbi.nlm.nih.gov/31234350 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20190813 $b ABA008
991    __
$a 20190815114918 $b ABA008
999    __
$a ind $b bmc $g 1433999 $s 1067310
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2019 $b 11 $c 6 $e 20190621 $i 2072-6694 $m Cancers $n Cancers $x MED00173178
GRA    __
$a Conceptual Development of Research Organization (Faculty Hospital in Pilsen - FNPl, 00669806) $p Ministry of Health of the Czech Republic
GRA    __
$a Project - UNCE/MED/006 - Project Centrum of clinical and experimental liver surgery $p Charles University Fund
LZP    __
$a Pubmed-20190813

Najít záznam

Citační ukazatele

Možnosti archivace